{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:29:05Z","timestamp":1792546145273,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtho.2024.03.008","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T03:39:32Z","timestamp":1709782772000},"page":"1073-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial"],"prefix":"10.1016","volume":"19","author":[{"given":"Ying","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiangjiin","family":"Leaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.03.008_bib1","first-page":"2945","article-title":"A\u00a02022 update on extensive stage small-cell lung cancer (SCLC)","volume":"13","author":"Oronsky","year":"2022","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.jtho.2024.03.008_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtho.2024.03.008_bib3","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.3390\/curroncol29120709","article-title":"Chemo-immunotherapy in first line extensive stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis","volume":"29","author":"Sathiyapalan","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2024.03.008_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.03.008_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from Caspian","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2024.03.008_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/onco.13752","article-title":"FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer","volume":"26","author":"Mathieu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2024.03.008_bib13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2024.03.008_bib14","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/2211-5463.13102","article-title":"Tislelizumab uniquely binds to the CC\u2019 loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage","volume":"11","author":"Hong","year":"2021","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.jtho.2024.03.008_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2024.03.008_bib17","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2024.03.008_bib20","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib23","author":"Tevimbra"},{"key":"10.1016\/j.jtho.2024.03.008_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2020.06.007","article-title":"A\u00a0phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients","volume":"147","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.03.008_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2019.01.01","article-title":"Chinese guidelines for diagnosis and treatment of primary lung cancer 2018. English version","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.jtho.2024.03.008_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","article-title":"Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study","volume":"125","author":"Cheng","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.03.008_bib28","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/1759-7714.13977","article-title":"Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: a comprehensive analysis of 358 patients","volume":"12","author":"Huang","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2024.03.008_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2017.11.022","article-title":"Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer","volume":"115","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.03.008_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/JTO.0b013e31819140fb","article-title":"Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity","volume":"4","author":"Ou","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/JTO.0000000000000142","article-title":"Small-cell lung cancers in patients who never smoked cigarettes","volume":"9","author":"Varghese","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/annonc\/mdu504","article-title":"Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing","volume":"26","author":"Sun","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.03.008_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4830","article-title":"Association of smoking with patient characteristics and outcomes in small cell lung carcinoma, 2011\u20132018","volume":"5","author":"Tseng","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2024.03.008_bib34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12890-022-01989-x","article-title":"Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea","volume":"22","author":"Kang","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jtho.2024.03.008_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cllc.2011.04.001","article-title":"Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke","volume":"13","author":"Kurahara","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.03.008_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21147\/j.issn.1000-9604.2022.03.03","article-title":"National guidelines for diagnosis and treatment of lung cancer 2022 in China. English version","volume":"34","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.jtho.2024.03.008_bib37","article-title":"Impact of brain metastases on treatment patterns and outcomes with first-line durvalumab plus platinum-etoposide in extensive-stage SCLC (CASPIAN): a brief report","volume":"3","author":"Chen","year":"2022","journal-title":"JTO Clin Res Rep"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:29:36Z","timestamp":1751398176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1556086424001151"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.03.008","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}